" class="no-js "lang="en-US"> ProJenX Announces Scientific Advisory Board for ALS Treatment
Saturday, June 08, 2024

ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment

ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, has announced the formation of its Scientific Advisory Board (SAB). The SAB, which includes internationally renowned experts in stem cell biology, ALS disease modeling and drug discovery, and clinical development across neurodegeneration, will provide strategic guidance for the development of ProJenX’s lead candidate prosetin—a brain-penetrant, orally available, MAP4K inhibitor—and additional pipeline expansion activities.

The inaugural members are Leonard van den Berg, MD, PhD (UMC Utrecht), Claire Henchcliffe, MD, DPhil (UC Irvine), Joe Lewcock, PhD (Denali Therapeutics), Lee Rubin, PhD (Harvard University), and Neil Shneider, MD, PhD (Columbia University).

Dr. Rubin, Professor of Stem Cell and Regenerative Biology at Harvard University and Co-Director of the Neuroscience Program at the Harvard Stem Cell Institute, said, “My own laboratory’s longstanding interest in patient-derived models of ALS and in the identification of neuroprotective compounds pointed us, much like ProJenX, to MAP4Ks as key regulators of motor neuron degeneration. I am excited by the research behind prosetin and look forward to working with ProJenX to elucidate and intervene in the key cellular pathways involved in ALS and neurodegeneration.”

“To meaningfully alter the course of disease in ALS, we must advance better-validated therapeutic candidates,” said Dr. Shneider, Director of the Eleanor and Lou Gehrig ALS Center and Claire Tow Associate Professor of Neurology at Columbia University Irving Medical Center. “The long-term collaboration between Columbia University researchers and Project ALS that led to prosetin is an example of the rational, scientifically rigorous approach required for clinical success, and I am eager to work with the ProJenX team to move prosetin forward in ALS.”

Erin Fleming, Co-Founder and Vice President of Research & Development at ProJenX, said, “We are honored to convene a world-class Scientific Advisory Board, who represent peerless experience and knowledge across ALS drug development, data-driven clinical trial design, and the MAP kinase pathway in neurodegeneration. With our advisors’ leadership, ProJenX is poised to translate decades of scientific discovery to people with ALS—beginning with prosetin.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more